Abstract
A collection of rifampin-resistant mutants of Staphylococcus aureus with characterized RNA polymerase beta-subunit (rpoB) gene mutations was cross-screened against a number of other RNA polymerase inhibitors to correlate susceptibility with specific rpoB genotypes. The rpoB mutants were cross-resistant to streptolydigin and sorangicin A. In contrast, thiolutin, holomycin, corallopyronin A, and ripostatin A retained activity against the rpoB mutants. The second group of inhibitors may be of interest as drug development candidates.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Antibiotics, Antitubercular / pharmacology
-
DNA-Directed RNA Polymerases / antagonists & inhibitors*
-
DNA-Directed RNA Polymerases / genetics
-
Drug Resistance, Microbial
-
Enzyme Inhibitors / pharmacology*
-
Lactams*
-
Lactones / pharmacology
-
Microbial Sensitivity Tests
-
Pyrrolidinones / pharmacology
-
Rifampin / pharmacology*
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / genetics
Substances
-
Anti-Bacterial Agents
-
Antibiotics, Antitubercular
-
Enzyme Inhibitors
-
Lactams
-
Lactones
-
Pyrrolidinones
-
ripostatin A
-
acetopyrrothine
-
holomycin
-
DNA-Directed RNA Polymerases
-
RNA polymerase beta subunit
-
Rifampin